Fenoldopam in critically ill patients with early renal dysfunction. A crossover study

Cardiovasc Ther. 2011 Aug;29(4):280-4. doi: 10.1111/j.1755-5922.2010.00217.x. Epub 2010 Oct 18.

Abstract

Background: Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an option to prevent further damage.

Methods: We performed a randomized, double-blinded, prospective crossover study in 17 patients admitted to our trauma intensive care unit (ICU) with evidence of impaired renal function. Patients were randomized to a 24-h intravenous infusion of low-dose fenoldopam or placebo. When the infusion of fenoldopam or placebo was completed, patients underwent a 24-h "washout" period in which no study intervention was performed. This sequence was repeated in each patient with the opposite agent, so each patient served as his own control. Four-hour creatinine collections were taken during the last 4 h of each infusion and washout periods to determine creatinine clearance changes during and after the administration of the study drug.

Results: The creatinine clearance was higher with fenoldopam infusion than with placebo infusion (P = 0.045). The FENa was not significantly different.

Conclusions: Our study showed that low-dose Fenoldopam increases creatinine clearance in the critically ill with renal insufficiency. Fenoldopam may be a useful drug in ICU patients with early renal dysfunction.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / physiopathology
  • Adult
  • Aged
  • Critical Illness
  • Cross-Over Studies
  • Dopamine Agonists / therapeutic use*
  • Double-Blind Method
  • Fenoldopam / therapeutic use*
  • Humans
  • Middle Aged
  • Prospective Studies

Substances

  • Dopamine Agonists
  • Fenoldopam